PerkinElmer (PKI) Tops Q4 EPS by 2c, Revenues Beat; Initiates Q1 & FY20 EPS Guidance Below Consensus

PerkinElmer (NYSE: PKI) reported Q4 EPS of $1.35, $0.02 better than the analyst estimate of $1.33. Revenue for the quarter came in at $805.5 million versus the consensus estimate of $800.98 million.

• 4Q Revenue of $805.5 million; 6% reported growth; 5% organic growth
• 4Q GAAP EPS from continuing operations of $0.58; Adjusted EPS of $1.35
• 4Q GAAP operating income margin of 17.2%; Adjusted operating income margin from continuing operations of 23.9%

“We are pleased with our strong finish to 2019. The rapid transformation we made as an organization over the past few years and in particular 2019 has put us in an excellent position to accelerate profitable growth and advance outcomes around the world in 2020 and beyond,” said Prahlad Singh, president and chief executive officer of PerkinElmer.

GUIDANCE:

PerkinElmer sees Q1 2020 EPS of $0.70, versus the consensus of $0.84. PerkinElmer sees Q1 2020 revenue of $700 million, versus the consensus of $699.93 million.

PerkinElmer sees FY2020 EPS of $4.50-$4.60, versus the consensus of $4.63. PerkinElmer sees FY2020 revenue of $3.05-3.09 billion, versus the consensus of $3.08 billion.

• Initiates FY20 GAAP EPS guidance range of $2.89 to $2.99 from continuing operations; Adjusted EPS guidance of $4.50 to $4.60; FY20 Revenue of $3.05 billion to $3.09 billion; 6-7% reported growth; 5-6% organic growth
• Initiates 1Q20 GAAP EPS guidance of $0.33 from continuing operations; Adjusted EPS guidance of $0.70; 1Q20 Revenue of $700 million; 8% reported growth; 6% organic growth

For earnings history and earnings-related data on PerkinElmer (PKI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Evogene chairman to address dissident shareholders on results call